Arbejdsmarkedets Tillaegspension Acquires 59,161 Shares of Medtronic PLC $MDT

Arbejdsmarkedets Tillaegspension grew its holdings in Medtronic PLC (NYSE:MDT) by 25.3% during the first quarter, HoldingsChannel.com reports. The firm owned 292,638 shares of the medical technology company’s stock after acquiring an additional 59,161 shares during the quarter. Arbejdsmarkedets Tillaegspension’s holdings in Medtronic were worth $25,357,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Monetary Solutions Ltd bought a new position in shares of Medtronic in the fourth quarter worth about $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic during the 4th quarter valued at about $27,000. Anfield Capital Management LLC lifted its holdings in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Medtronic during the 4th quarter valued at about $29,000. Finally, GoalVest Advisory LLC purchased a new stake in Medtronic in the 4th quarter valued at about $29,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MDT. Wells Fargo & Company dropped their target price on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. TD Cowen lowered their price target on Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a report on Friday. Robert W. Baird dropped their price objective on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Truist Financial dropped their price objective on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research note on Thursday, June 4th. Finally, Citigroup reduced their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Seventeen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.17.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: TD Cowen cut its price target on Medtronic to $100 from $119 but kept a buy rating, signaling the stock still has meaningful upside from current levels. TD Cowen lowers price target on Medtronic
• Positive Sentiment: Another recent bullish note said Medtronic’s guidance is conservative and “built to be beaten,” highlighting strong fiscal 2026 revenue growth and potential upside catalysts from the MiniMed separation, tariff refunds, and payment relief. Medtronic guidance built to be beaten
• Positive Sentiment: Another Seeking Alpha article argued Medtronic is undervalued and that tailwinds are just beginning, reinforcing the idea that investors may be underappreciating the company’s growth potential. Medtronic undervalued and tailwinds just getting started
• Positive Sentiment: Citi also reportedly initiated or reiterated a buy view on Medtronic, adding to the wave of favorable analyst sentiment. Medtronic receives a buy from Citi
• Neutral Sentiment: Medtronic disclosed a voluntary global recall of its Octopus 4 Tissue Stabilizer after an assembly issue affecting 590 units. The issue appears limited, but recalls can create short-term investor caution. Medtronic recalls Octopus 4 Tissue Stabilizer
• Neutral Sentiment: Separate valuation pieces on Medtronic suggest the stock remains cheap relative to fundamentals, but these are more interpretation than hard catalysts for the share price. Medtronic stock could be undervalued

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Medtronic Trading Down 0.1%

NYSE:MDT opened at $83.78 on Monday. The firm has a 50-day simple moving average of $79.11 and a 200-day simple moving average of $88.46. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The firm has a market cap of $107.24 billion, a P/E ratio of 22.46, a P/E/G ratio of 2.25 and a beta of 0.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the company posted $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be issued a $0.72 dividend. The ex-dividend date is Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. This is a boost from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).